Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid and BioMerieux to Develop, Market Sepsis Assays

NEW YORK (GenomeWeb News) — Cepheid and BioMerieux plan to develop and market a line of sepsis tests, the companies said today.
 
The companies said they will develop assays to identify fungi and bacteria and genetic markers for antibiotic resistance. Cepheid and BioMerieux also said that the panel could be used to identify hospital-acquired pneumonia.
 
The tests will work on Cepheid’s GeneXpert platform. Cepheid will manufacture them and BioMerieux will distribute them worldwide.
 
As part of the deal, BioMerieux has licensed Cepheid patents for its methicillin-resistant Staphylococcus aureus test. Cepheid will continue to develop, manufacture, and market the products
 
Financial terms of the agreement were not released.
 
Sepsis is a bacterial infection of the bloodstream that affects a small percentage of hospital patients, generally those with depressed immune systems. The condition affects around 750,000 Americans each year and results in death in between a quarter and a half of them. US hospitals $17 billion a year treating the infections, the companies said.
 
Cepheid CEO John Bishop said a rapid sepsis test coupled with a “molecular snapshot of drug-resistant organisms” will allow doctors to make better treatment decisions more quickly.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.